NCT03778112Active, not recruiting
MRI Guided SBRT for Localized Prostate Cancer
Prospective Evaluation of Multi-Parametric MRI Guided Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
This study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify patients for two different radiotherapy regimens based on the presence/absence of identifiable intraprostatic lesions. In patients without identifiable prostate cancer lesions, SBRT to the prostate in 5 sessions (fractions) will be administered. In patients with MRI-identified lesion(s), pelvic IMRT in 25 fractions will be administered followed by an SBRT prostate boost while simultaneously treating the prostate cancer lesion(s) to a higher dose in 3 fractions.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 54 (actual)
- First submitted
- 14 Dec 2018
- Start date
- 23 May 2016
- Primary completion date
- Mar 2019
- Lead sponsor
- Rush University Medical Center
- Diseases
- Prostate cancer
- NCT number
- NCT03778112
What you commit to
- Study type: Interventional
- Participants enrolled: 54
- From 23 May 2016 to the primary completion date, Mar 2019
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior or concurrent invasive malignancy (except non-melanoma skin cancer)
- History of prior pelvic irradiation (external beam radiotherapy or brachytherapy)
- Prior chemotherapy
Other illness
- Severe, active co-morbidities (unstable angina and/or CHF; MI; COPD; liver disease; AIDS)
- Acute bacterial or fungal infection requiring IV antibiotics
Other
- Regional Lymph Node (N1) involvement
- Distant Metastases (M1) involvement
- Inability to undergo MRI
- Inability to receive fiducial markers
Who the study is looking for
- Biopsy proven prostate adenocarcinoma within 1 year of randomization
- NCCN Low to High Risk localized prostate cancer
- Zubrod Performance Status 0-1 within 60 days prior to registration
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rush University Medical Center Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.